Team: Jonathan Siller (Leukemia Fellow), Rena Seeger (Summer Research Student), Veronica Nievas (Critical Care Fellow), Laveena Munshi (Critical Care) and Tracy Murphy (Leukemia)
Background
Hyperleukocytosis can result in leukostasis leading to end organ dysfunction, spontaneous tumor lysis syndrome (TLS) and disseminated intravascular coagulopathy (DIC). If leukostasis is not recognized or treated promptly, 20-40% will die within 7 days. However, institutional practice on how patients with hyperleukocytosis are managed varies internationally.
Objective
To describe the incidence, characteristics, management practices and outcomes of patients with AML and hyperleukocytosis and leukostasis.